Repository logo

Wnt Inhibition Facilitates RNA-Mediated Reprogramming of Human Somatic Cells to Naive Pluripotency.

Accepted version



Change log


Bredenkamp, Nicholas 
Yang, Jian 
Stirparo, Giuliano Giuseppe 
von Meyenn, Ferdinand 


In contrast to conventional human pluripotent stem cells (hPSCs) that are related to post-implantation embryo stages, naive hPSCs exhibit features of pre-implantation epiblast. Naive hPSCs are established by resetting conventional hPSCs, or are derived from dissociated embryo inner cell masses. Here we investigate conditions for transgene-free reprogramming of human somatic cells to naive pluripotency. We find that Wnt inhibition promotes RNA-mediated induction of naive pluripotency. We demonstrate application to independent human fibroblast cultures and endothelial progenitor cells. We show that induced naive hPSCs can be clonally expanded with a diploid karyotype and undergo somatic lineage differentiation following formative transition. Induced naive hPSC lines exhibit distinctive surface marker, transcriptome, and methylome properties of naive epiblast identity. This system for efficient, facile, and reliable induction of transgene-free naive hPSCs offers a robust platform, both for delineation of human reprogramming trajectories and for evaluating the attributes of isogenic naive versus conventional hPSCs.



RNA-mediated reprogramming, Wnt signaling, human pluripotent stem cells, human pre-implantation epiblast, induced pluripotent stem cells, molecular reprogramming, naive pluripotency, Biomarkers, Cellular Reprogramming, Fibroblasts, Gene Expression Profiling, Humans, Induced Pluripotent Stem Cells, RNA, RNA, Messenger, Reproducibility of Results, Signal Transduction, Wnt Proteins

Journal Title

Stem Cell Reports

Conference Name

Journal ISSN


Volume Title



Elsevier BV


All rights reserved
Medical Research Council (G1001028)
European Commission (602423)
Medical Research Council (MR/P00072X/1)
This research was funded by the Medical Research Council of the United Kingdom (G1001028 and MR/P00072X/1) and European Commission Framework 7 (HEALTHF4-2013-602423, PluriMes). JY was supported by the Guangdong Provincial Key Laboratory, and FvM by a UKRI/MRC Rutherford Fund Fellowship. The Cambridge Stem Cell Institute receives core support from Wellcome and the Medical Research Council. AS is a Medical Research Council Professor.